Yinjia Bio
引加生物
Yinjia Bio (引加生物) is a Shanghai-based protein technology platform founded at the end of 2020, positioned as a developer of high-end proteins for biopharmaceutical upstream supply . It has built a proprietary protein optimization platform and expanded into GMP production and single-cell multi-functional protein analysis . The company has raised three rounds totaling several hundred million RMB, with Gaorong Ventures leading its Pre-A round in mid-2021 and CMB International leading its ~RMB 100 million Series A in early 2023 . Beyond fundraising, Yinjia has pursued strategic partnerships in the cell and gene therapy space, including a collaboration with Boteng Bio announced in early 2023 to develop core protein raw materials and quality-control reagents , and has been referenced as a co-development partner for protein and antibody drug products with firms applying generative AI to bio-manufacturing .
AI-generated — may contain errors, please verify.
Coverage
BioGeometry Completes Pre-A Round, Applying Generative AI to Bio-Manufacturing
Continuously optimizing a generative AI-powered protein design platform.
Medical Device/Chip Companies Close New Funding Rounds, Driving High-Quality Growth Through R&D, Commercialization, and Supply Chain | Rong Report · February
Infinite possibilities for creating a better life.
Yinjia Biotech Closes Nearly RMB 100 Million Series A Round to Accelerate Buildout of Upstream Core Protein Ingredient Synthetic Biology Platform
Staying true to our mission as "protein craftsmen."
Rongbao · July | Multiple Companies Close New Funding Rounds, Take the Lead in Their Sectors; Pinduoduo's Olympic Season Boosts Sports Consumption for All
Continue to invest in innovative companies in new consumer brands, new technologies, healthcare, and other sectors.
Yinjia Biotech Closes Pre-A Round, Advancing Its High-End Protein Platform to New Heights
Build a leading domestic "protein artisan" platform.
